1
|
de Germay S, Singier A, Salvo F, Pariente A. Impact of Covid-19 Vaccination on Spontaneous Pharmacovigilance Reporting in France. Drug Saf 2023; 46:1381-1389. [PMID: 37926785 DOI: 10.1007/s40264-023-01359-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/27/2023] [Indexed: 11/07/2023]
Abstract
INTRODUCTION In 2021, the massive Covid-19 vaccination campaign in France was accompanied by an intensified pharmacovigilance monitoring of their potential adverse drug reactions. The importance of this reporting might have led to an important selective reporting and overloading of Pharmacovigilance Centres, delaying the recording of some reports in the national pharmacovigilance database. In this context, we aimed to evaluate the impact of the Covid-19 vaccination campaign in France and related reports on spontaneous reporting of adverse drug reactions that were not related to the Covid-19 vaccine. METHODS We performed time-series analyses considering the monthly number of adverse drug reactions reported between January 1, 2018 and April 30, 2022 using the French Pharmacovigilance database. The impact of the Covid-19 vaccination campaign on the monthly reporting not Covid-19 vaccine related was estimated using interrupted time-series. January 2021, marking the start of the campaign, was the intervention date in the models. Analyses were run globally first considering all adverse drug reaction reports, and second according to notifier type and to case seriousness. RESULTS We included 170,294 reports registered in the French Pharmacovigilance database between January 1, 2018 and April 30, 2022 that were not Covid-19 vaccine-related. Among these, 77,067 (45.3%) were serious and 146,683 (86.1%) had been reported by health care professionals. The campaign start was associated with a nearly 35.0% decrease in average monthly reporting that was not Covid-19 vaccine-related, with a significant level decrease in the monthly number of reports of -658.0 (p < 10-3) immediately after the vaccination campaign start and a subsequent slope decrease of -50.0 (p < 10-3). This decrease was mainly due to a significant level and slope decrease (level: -739.2 p < 10-3; slope: -39 [p < 10-2]) for health care professional reports. A similar level decrease was found for the monthly number of both serious and non-serious reports (-402.3, p < 10-3; and -311.9, p = 10-2, respectively). According to the ATC 1 level, the decrease in the monthly number of reports showed similar patterns for all drugs. However, a potential increase in the number of serious reports suspecting antineoplastic and immunomodulating drugs (ATC L) or drugs targeting blood was observed (ATC B). CONCLUSION Our study showed a significant impact of the Covid-19 campaign vaccination in the reporting of adverse drug reactions that were not Covid-19 vaccine-related, of roughly 35%. This leads to a loss of information regarding the monitoring of drug safety that could have impacted the system capacity to detect safety signals for drugs other than Covid-19 vaccines.
Collapse
Affiliation(s)
- Sibylle de Germay
- INSERM, BPH, U1219 Team AHead, University of Bordeaux, 33000, Bordeaux, France.
- Department of Medical Pharmacology, CHU of Bordeaux, 33000, Bordeaux, France.
| | - Allison Singier
- INSERM, BPH, U1219 Team AHead, University of Bordeaux, 33000, Bordeaux, France
| | - Francesco Salvo
- INSERM, BPH, U1219 Team AHead, University of Bordeaux, 33000, Bordeaux, France
- Department of Medical Pharmacology, CHU of Bordeaux, 33000, Bordeaux, France
| | - Antoine Pariente
- INSERM, BPH, U1219 Team AHead, University of Bordeaux, 33000, Bordeaux, France
- Department of Medical Pharmacology, CHU of Bordeaux, 33000, Bordeaux, France
| |
Collapse
|
2
|
Salvo F, Pariente A, Valnet-Rabier MB, Drici MD, Cholle C, Mathieu C, Singier A, Bagheri H, Tebacher M, Micallef J, Gautier S. Role of spontaneous reporting in investigating the relationship between mRNA COVID-19 vaccines and myocarditis: The French perspective. Therapie 2023; 78:509-515. [PMID: 37012151 PMCID: PMC9990878 DOI: 10.1016/j.therap.2023.03.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Accepted: 03/06/2023] [Indexed: 03/09/2023]
Abstract
AIM OF THE STUDY Post-mRNA coronavirus diseases 2019 (COVID-19) vaccines myocarditis emerged as a rare adverse effect, particularly in adolescents and young adults, and was labeled as such for both vaccines in the summer of 2021. This study aims to summarize the timeline and process of signal detection, substantiation, and quantification of myocarditis cases related to mRNA vaccines in France. METHODS The intensive monitoring plan for COVID-19 vaccine safety was based on case-by-case analysis of all cases collected in the French spontaneous reporting database (Base nationale de pharmacovigilance, BNPV). Cases were evaluated by drug safety medical professionals and discussed at a national level for signal detection purposes. Reported cases were compared to the number of vaccine-exposed persons up to September 30th, 2021. Reporting rates (Rr) of myocarditis per 100,000 injections were calculated and stratified according to age, gender, and injection rank of BNT162b2 and mRNA-1273 vaccines. Poisson distribution was used to compute Rrs 95% Confidence Interval (95% CI). RESULTS The case-by-case analysis detected a possible cluster of myocarditis in April 2021 (5 cases, 4 after the 2nd injection). In June 2021, the signal was substantiated with 12 cases (9 related to BNT162b2, and 3 to mRNA-1273). As of September 2021, almost 73 million BNT162b2 and 10 million mRNA-1273 doses had been injected. The Rr per 100,000 injections was 0.5 (0.5-0.6) for BNT162b2 and 1.1 (95% CI 0.9-1.3) for mRNA-1273. The difference among vaccines was more pronounced after the second injection, particularly in men aged 18-24 years (4.3 [3.4-5.5] for BNT162b2 vs. 13.9 [9.2-20.1] for mRNA-1273) and aged 25-29 years (1.9 [1.2-2.9] vs. 7.0 [3.4-12.9]). CONCLUSION The study highlighted the role of the spontaneous reporting system in the detection, assessment, and quantification of myocarditis related to m-RNA vaccines. It suggested from September 2021 that mRNA-1273 was reasonably related to a higher risk of myocarditis than BNT162b2 in people under 30, particularly after the second injection.
Collapse
Affiliation(s)
- Francesco Salvo
- Inserm U1219, Department of Medical Pharmacology, Université de Bordeaux, University Hospital of Bordeaux, Regional pharmacovigilance Center of Bordeaux, 33000 Bordeaux, France.
| | - Antoine Pariente
- Inserm U1219, Department of Medical Pharmacology, Université de Bordeaux, University Hospital of Bordeaux, Regional pharmacovigilance Center of Bordeaux, 33000 Bordeaux, France
| | - Marie Blanche Valnet-Rabier
- Department of Medical Pharmacology, Regional Pharmacovigilance Center, University Hospital of Besançon, 25030 Besançon, France
| | - Milou-Daniel Drici
- Department of Pharmacology, Côte d'Azur University Medical Center, 06003 Nice, France
| | - Clement Cholle
- Inserm U1219, Department of Medical Pharmacology, Université de Bordeaux, University Hospital of Bordeaux, Regional pharmacovigilance Center of Bordeaux, 33000 Bordeaux, France
| | - Clement Mathieu
- Inserm U1219, Université de Bordeaux, 33000 Bordeaux, France
| | - Allison Singier
- Inserm U1219, Université de Bordeaux, 33000 Bordeaux, France
| | - Haleh Bagheri
- Department of Medical Pharmacology, Regional Pharmacovigilance Center, University Hospital of Toulouse, 31000 Toulouse, France
| | - Martine Tebacher
- University Hospital of Strasbourg, Regional Pharmacovigilance Center, 67091 Strasbourg, France
| | - Joelle Micallef
- Inserm 1106, Department of Pharmacology & Pharmacovigilance, Regional Pharmacovigilance Center, Aix-Marseille University UMR, 13274 Marseille, France
| | - Sophie Gautier
- Department of Pharmacology, Regional Pharmacovigilance Center of Lille, University Hospital of Lille, UMR 1172, University Lille, 59000 Lille, France
| |
Collapse
|
3
|
Jonville-Bera AP, Gautier S, Micallef J, Massy N, Atzenhoffer M, Grandvuillemin A, Drici MD. Monitoring the safety of drugs and COVID-19 vaccines by the French Pharmacovigilance Centers during the pandemic: A win-win bet with Health Authorities! Therapie 2023; 78:467-475. [PMID: 37012154 PMCID: PMC9990876 DOI: 10.1016/j.therap.2023.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2023] [Accepted: 02/28/2023] [Indexed: 03/09/2023]
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) pandemic virus was a "health crisis" and a significant burden also for the French pharmacovigilance system. It took its toll in 2 phases, the first being in early 2020 when very little was known, and during which the missions of the 31 Regional Pharmacovigilance Centers (RPVCs) from university hospitals were to detect adverse reactions of drugs used in the context of the disease. Whether as a possible aggravating role on COVID-19, or displaying a different safety profile during its course, or to assess safety of curative treatment, this phase preceded that of the arrival of dedicated vaccines. Then the RPVCs' missions were to detect, as early as possible, any new serious adverse effect leading to a potential signal that would modify the benefit/risk ratio of a vaccine and require the implementation of health safety measures. During these two distinct periods, signal detection remained the core business of the RPVCs. Each RPVC had to organize itself to handle an unprecedented surge of declarations and requests for advice, from health care professionals and patients alike. "Leading" RPVCs, who were in charge of monitoring vaccines, had to deal with an extraordinary workload (still going on to this date), to generate in real-time and on a weekly basis, a summary of all the adverse drug reaction (ADR) reports as well as an extended analysis of the different safety signals. The organization put in place at the beginning of the health crisis, adapted to the context of the vaccines, allowed to meet the challenge of real-time pharmacovigilance monitoring, and to identify many safety signals. Efficient "short-circuits exchanges" with the French Regional Pharmacovigilance Centers Network (RPVCN) were paramount to the National Agency for the Safety of Medicines and Health Products (ANSM) to develop an optimal collaborative partnership. The French RPVCN has shown at this occasion both agility and flexibility, swiftly adapting to vaccine- and media-related unrest, and demonstrated its effectiveness in the early detection of safety signals. This crisis also confirmed the superiority of manual/human signal detection over automated ones, as the most effective and powerful tool to date to rapidly detect and validate a new ADR and enable to elaborate rapid risk reduction measures. To maintain the performance of French RPVCN in signal detection and to monitor all drugs as they should, and as expected by our fellow citizens, a new funding model should be considered.
Collapse
Affiliation(s)
- Annie Pierre Jonville-Bera
- Service de pharmacosurveillance, centre régional de pharmacovigilance, centre Val de Loire, CHRU de Tours, 37000 Tours, France.
| | - Sophie Gautier
- Service de pharmacologie, centre régional de pharmacovigilance Nord Pas de Calais, CHRU de Lille, 59000 Lille, France
| | - Joëlle Micallef
- Service de pharmacologie, centre régional de pharmacovigilance, et université d'Aix Marseille, APHM, INSERM, Inst Neurosci Syst, UMR 1106, 13005 Marseille, France
| | - Nathalie Massy
- Service de pharmacologie médicale, centre régional de pharmacovigilance de Rouen, CHRU de Rouen, 76000 Rouen, France
| | - Marina Atzenhoffer
- Centre régional de pharmacovigilance, hospices civils de Lyon, 69000 Lyon, France
| | - Aurélie Grandvuillemin
- Service de pharmacologie, centre régional de pharmacovigilance de Nice, CHRU de Nice, 06000 Nice, France
| | - Milou-Daniel Drici
- Centre régional de pharmacovigilance de Bourgogne, CHRU de Dijon, 21000 Dijon, France
| |
Collapse
|
4
|
Grandvuillemin A, Rocher F, Valnet-Rabier MB, Drici MD, Dautriche A. Pharmacovigilance follow-up of patients in the context of the COVID-19 pandemic. Therapie 2023; 78:523-529. [PMID: 36754694 PMCID: PMC9851716 DOI: 10.1016/j.therap.2023.01.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2022] [Accepted: 12/08/2022] [Indexed: 01/21/2023]
Abstract
INTRODUCTION In the context of COVID-19 pandemic, a national pharmacovigilance survey was set up in March 2020. The purpose of this survey was to ensure continuous monitoring of adverse drug reactions (ADRs) in patients with COVID-19, not only related to the drugs used in this indication but also related to all drugs administered to these patients or suspected of having promoted the infection. MATERIAL AND METHODS This descriptive study was based on data extracted from the French Pharmacovigilance Database from 1 January 2020 to 30 September 2021. Misuse was also analysed through the MESANGE project. The ADRs were classified according to three groups: "drugs used to treat COVID-19", "other drugs administered to COVID-19 positive patients" and "drugs suspected of having promoted COVID-19". The data were also presented according to 2 periods (period one was from January to June 2020 and period two from July 2020 onwards). RESULTS Among 2189 included cases, 67.1% were serious. Cases were mainly related to "other drugs administrated to COVID-19 positive patients" (58.5%) followed by "drugs used to treat COVID-19" (33.7%) and "drugs suspected of having promoted COVID-19" (7.8%). Drugs used to treat COVID-19 and their main safety profile were different depending on the period: mostly hydroxychloroquine (51%) with heart injury and lopinavir/ritonavir (42%) with liver injury for the first period, and dexamethasone (46%) with hyperglycemia and tocilizumab (28%) with liver injury for the second period. The drugs suspected of worsening COVID-19 differed in both periods especially for non-steroidal anti-inflammatory drugs mainly reported in period 1 (41.5% versus 8.2% in period 2). Other immunosuppressive drugs were in the majority in the second period (85.7%), with mainly methotrexate (15.3%), anti-CD20 (15.3%) and anti-TNF alpha (10.5%). No confirmed safety signal was identified among other drugs administered to patients with COVID-19. The profile of ADRs and suspected drugs was similar between the 2 periods. The study of misuse in outpatient settings identified in both periods mainly hydroxychloroquine, azithromycin, ivermectin and zinc±vitamin C. DISCUSSION This survey, based on real-time pharmacological and medical assessment of ADRs and weekly meetings in a specific national committee, made it possible to identify relevant safety signals which contribute to patient care with no delay. The main safety signal highlighted was serious cardiac damage under hydroxychloroquine, alone or combined with azithromycin and also with lopinavir/ritonavir. This signal has contributed to the evolution of the recommendations for these 2 drugs. The methodology of this survey has been taken over and is still going on for the pharmacovigilance monitoring of vaccines against COVID-19, for monoclonal antibodies used against COVID-19 and also for Paxlovid® (nirmatrelvir/ritonavir) which benefit from dedicated surveys.
Collapse
Affiliation(s)
- Aurélie Grandvuillemin
- Centre régional de pharmacovigilance de Bourgogne, University Hospital, 21079 Dijon, France.
| | - Fanny Rocher
- Pharmacovigilance, Department of Pharmacology, Pasteur Hospital, 06001 Nice, France
| | | | - Milou-Daniel Drici
- Pharmacovigilance, Department of Pharmacology, Pasteur Hospital, 06001 Nice, France
| | - Anne Dautriche
- Centre régional de pharmacovigilance de Bourgogne, University Hospital, 21079 Dijon, France
| |
Collapse
|
5
|
Jonville-Bera AP, Gautier S, Micallef J, Massy N, Atzenhoffer M, Drici MD, Grandvuillemin A. [Monitoring the safety of drugs and COVID-19 vaccines by the French Pharmacovigilance Centers during the pandemic: a win-win bet with Health Authorities!]. Therapie 2023; 78:477-488. [PMID: 36890032 PMCID: PMC9943552 DOI: 10.1016/j.therap.2023.02.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2023] [Accepted: 02/21/2023] [Indexed: 02/23/2023]
Abstract
The pandemic subsequent to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus resulted, for the French institutional pharmacovigilance, in a "health crisis" in 2 phases: the coronavirus disease 2019 - "COVID-19" phase during which the missions of the Regional Pharmacovigilance Centres (RPVC) were to detect a possible impact of drugs on this disease, as whether existed a possible aggravating role of certain drugs, or the safety profile of drugs used for the management of COVID-19 could evolve. The second phase followed the availability of COVID-19 vaccines, during which the RPVCs' missions were to detect as early as possible any new serious adverse effect, source of a potential signal that would modify the benefit/risk ratio of a vaccine and require the implementation of health safety measures. During these two periods, signal detection remained the core business of the RPVCs. The RPVCs had to organize themselves to handle an historical surge of declarations and requests for advice, whereas the RPVCs in charge of monitoring vaccines had to deal with an extraordinary dense activity over a long period of time, in order to produce in real time and on a weekly basis, a summary of all the declarations and an analysis of safety signals. The national organization put in place made it possible to meet the challenge of real-time pharmacovigilance monitoring of 4 vaccines with conditional marketing authorizations. Short-circuit efficient exchanges with the French Regional Pharmacovigilance Centres Network was paramount for the French National Agency for medicines and health products (Agence nationale de sécurité du médicament et des produits de santé) to develop an optimal collaborative partnership. The RPVC network has shown agility and flexibility, has been able to adapt swiftly and demonstrated its effectiveness in the early detection of safety signals. This crisis confirmed the superiority of manual/human signal detection as the most effective and powerful tool to date, to rapidly detect a new adverse drug reaction and enable to elaborate rapid measures of risk reduction. In order to maintain the performance of French RPVCs in signal detection and to monitor all drugs as they should and as expected by our fellow citizens, a new funding model correcting the inadequacy of RPVCs' expertise resources in relation to the volume of reports should be considered.
Collapse
Affiliation(s)
- Annie Pierre Jonville-Bera
- Service de pharmacosurveillance, centre régional de pharmacovigilance Centre Val de Loire, CHRU de Tours, 37000 Tours, France.
| | - Sophie Gautier
- Service de pharmacologie, centre régional de pharmacovigilance Nord Pas de Calais, CHRU de Lille, 59000 Lille, France
| | - Joëlle Micallef
- Inserm, service de pharmacologie, université d'Aix-Marseille, UMR 1106, APHM, centre régional de pharmacovigilance, institut de neuroscience des systèmes, 13005 Marseille, France
| | - Nathalie Massy
- Service de pharmacologie médicale, centre régional de pharmacovigilance de Rouen, CHRU de Rouen, 76000 Rouen, France
| | - Marina Atzenhoffer
- Centre régional de pharmacovigilance, hospices civils de Lyon, 69000 Lyon, France
| | - Milou-Daniel Drici
- Service de pharmacologie, centre régional de pharmacovigilance de Nice, CHRU de Nice, 06000 Nice, France
| | | |
Collapse
|
6
|
Angeli-Silva L, Santos JVPD, Esperidião MA. Health system, surveillance and the COVID-19 pandemic response in France. CIENCIA & SAUDE COLETIVA 2023; 28:1313-1324. [PMID: 37194867 DOI: 10.1590/1413-81232023285.11202022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2022] [Accepted: 01/17/2023] [Indexed: 05/18/2023] Open
Abstract
France was the first European country to confirm cases of COVID-19, being one of the most affected by the pandemic in the first wave. This case study analyzed the measures adopted by the country in the fight against COVID-19 in 2020 and 2021, correlating it to the characteristics of its health and surveillance system. As a welfare state, it relied on compensatory policies and protection of the economy, as well as increased investments in health. There were weaknesses in the preparation and delay in the implementation of the coping plan. The response was coordinated by the national executive power, adopting strict lockdowns in the first two waves, mitigating restrictive measures in the other waves, after the increase in vaccination coverage and in the face of population resistance. The country faced problems with testing, case and contact surveillance and patient care, especially in the first wave. It was necessary to modify the health insurance rules to expand coverage, access and better articulation of surveillance actions. It indicates lessons learned about the limits of its social security system, but also the potential of a government with a strong response capacity in the financing of public policies and regulation of other sectors to face the crisis.
Collapse
Affiliation(s)
- Livia Angeli-Silva
- Escola de Enfermagem, Universidade Federal da Bahia. R. Basílio da Gama 241, Canela. 40231-300 Salvador BA Brasil.
| | | | | |
Collapse
|
7
|
Quelle place pour l’automatisation intelligente et l’intelligence artificielle pour préserver et renforcer l’expertise en vigilance devant l’augmentation des déclarations ? Therapie 2023; 78:115-129. [PMID: 36577617 DOI: 10.1016/j.therap.2022.11.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
8
|
Pariente A, Micallef J, Lahouegue A, Molimard M, Auffret M, Chouchana L, Denis B, Faillie JL, Grandvuillemin A, Letinier L, Pierron E, Pons C, Pujade I, Rubino H, Salvo F. What place for intelligent automation and artificial intelligence to preserve and strengthen vigilance expertise in the face of increasing declarations? Therapie 2023; 78:131-143. [PMID: 36572627 DOI: 10.1016/j.therap.2022.11.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
In 2018, the "Ateliers de Giens" (Giens Workshops) devoted a workshop to artificial intelligence (AI) and led its experts to confirm the potential contribution and theoretical benefit of AI in clinical research, pharmacovigilance, and in improving the efficiency of care. The 2022 workshop is a continuation of this reflection on AI and intelligent automation (IA) by focusing on its contribution to pharmacovigilance and the applications and tasks could be optimized to preserve and strengthen medical and pharmacological expertise in pharmacovigilance. The evolution of pharmacovigilance work is characterized by many tasks with low added value, a growing volume of pharmacovigilance reporting of suspected side effects, and a scarcity of medical staff with expertise in clinical pharmacology and pharmacovigilance and human resources to support this growing need. Together, these parameters contribute to an embolization of the pharmacovigilance system at risk of missing its primary mission: to identify and characterize a risk or even a health alert on a drug. The participants of the workshop (representatives of the Regional Pharmacovigilance Centres (CRPV), the French National Agency for Safety of Medicinal Products (ANSM), patients, the pharmaceutical industry, or start-ups working in the development of AI in the field of medicine) shared their experiences, their pilot projects and their expectations on the expected potential, theoretical or proven, AI and IA. This work has made it possible to identify the needs and challenges that AI or IA represent, in the current or future modes of organization of pharmacovigilance activities. This approach led to the development of a SWOT matrix (strengths, weaknesses, opportunities, threats), a basis for reflection to identify critical points and consider four main recommendations: (1) preserve and develop business expertise in pharmacovigilance (including research and development in methods) with the integration of new technologies; (2) improve the quality of pharmacovigilance reports; (3) adapt technical and regulatory means; (4) implement a development strategy for AI and IA tools at the service of expertise.
Collapse
Affiliation(s)
- Antoine Pariente
- Univ. Bordeaux, Inserm, BPH, U1219, Equipe AHeaD, 33000 Bordeaux, France; CHU de Bordeaux, service de Pharmacologie Médicale, 33000 Bordeaux, France.
| | - Joëlle Micallef
- AMU INS Inserm 1106, centre régional de pharmacovigilance, pharmacologie clinique, APHM, 13005 Marseille, France
| | - Amir Lahouegue
- Pharmacovigilance et information médicale, AstraZeneca, 92400 Courbevoie, France
| | - Mathieu Molimard
- Univ. Bordeaux, Inserm, BPH, U1219, Equipe AHeaD, 33000 Bordeaux, France; CHU de Bordeaux, service de Pharmacologie Médicale, 33000 Bordeaux, France
| | - Marine Auffret
- Service hospitalo-universitaire de pharmacotoxicologie, centre régional de pharmacovigilance, hospices civils de Lyon, UMR CNRS 5558, université de Lyon 1, 69000 Lyon, France
| | - Laurent Chouchana
- Service de pharmacologie, centre-université Paris Cité, centre régional de pharmacovigilance, hôpital Cochin, AP-HP, 75014 Paris, France
| | - Bernard Denis
- Formation recherche, union francophone patients partenaire, 75012 Paris, France
| | - Jean Luc Faillie
- Inserm, département de pharmacologie médicale et toxicologie, centre régional de pharmacovigilance, institut Desbrest d'épidémiologie et de santé publique, CHU de Montpellier, université Montpellier, 34090 Montpellier, France
| | | | | | - Evelyne Pierron
- Agence nationale de sécurité du médicament et des produits de santé (ANSM), 93285 Saint-Denis, France
| | | | | | - Heather Rubino
- Pfizer, Inc, 235, East 42nd Street, NYC, NY, 10007 New York, USA
| | - Francesco Salvo
- Univ. Bordeaux, Inserm, BPH, U1219, Equipe AHeaD, 33000 Bordeaux, France; CHU de Bordeaux, service de Pharmacologie Médicale, 33000 Bordeaux, France
| |
Collapse
|
9
|
Palassin P, Bres V, Hassan S, Alfonsi A, Massy N, Gras-Champel V, Maria ATJ, Faillie JL. Comprehensive description of adult-onset Still's disease after COVID-19 vaccination. J Autoimmun 2023; 134:102980. [PMID: 36592513 PMCID: PMC9755011 DOI: 10.1016/j.jaut.2022.102980] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Revised: 12/07/2022] [Accepted: 12/11/2022] [Indexed: 12/23/2022]
Abstract
Cases of adult-onset Still's disease (AOSD) have been reported after COVID-19 vaccination. Here we provide a comprehensive description and analysis of all cases of AOSD reported in the literature and in pharmacovigilance databases through April 2022. Disproportionality analyses of pharmacovigilance data were performed in order to further explore the association between vaccination and AOSD. We included 159 patients, 144 from the World Health Organization pharmacovigilance database and 15 from the literature. Detailed clinical characteristics were described for the cases from the literature and from the French pharmacovigilance database (n = 9). The cases of AOSD after COVID-19 vaccination concerned women in 52.2% of cases. The median age was 43.4 years. More than 80% of AOSD reports occurred during the first three weeks and concerned mostly the BNT162b2 mRNA vaccine. We identified 14.5% of disease flare with a median time-to-onset of AOSD flare-up significantly shorter than for the new onset form. More than 90% patients received steroids. Although all cases were considered serious and required hospitalization, most cases presented a favorable outcome (67.1%) with a good response to corticosteroid therapy with a mean time to recovery of 7.2 days. Disproportionality analyses suggested that AOSD was associated with COVID-19 vaccines as well as other vaccines. AOSD was nearly five times more frequently reported with COVID-19 vaccines than with all other drugs. Clinicians should be informed about the potential risk of AOSD onset or flare following COVID vaccines and the importance of its early detection to optimize its management.
Collapse
Affiliation(s)
- Pascale Palassin
- Department of Medical Pharmacology and Toxicology, CHU Montpellier, Montpellier, France.
| | - Virginie Bres
- Department of Medical Pharmacology and Toxicology, CHU Montpellier, Montpellier, France
| | | | - Ange Alfonsi
- Department of Medical Pharmacology and Toxicology, CHU Montpellier, Montpellier, France
| | - Nathalie Massy
- Regional Pharmacovigilance Center, Department of Pharmacology, CHU Rouen, Rouen, France
| | - Valérie Gras-Champel
- Regional Pharmacovigilance Center, Department of Clinical Pharmacology, CHU Amiens-Picardie, Amiens, France
| | - Alexandre Thibault Jacques Maria
- Internal Medicine & Immuno-Oncology (MedI2O), Institute for Regenerative Medicine and Biotherapy (IRMB), Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France,Univ Montpellier, IRMB, Montpellier, France
| | - Jean-Luc Faillie
- Department of Medical Pharmacology and Toxicology, CHU Montpellier, Montpellier, France,Univ Montpellier, IDESP INSERM, Montpellier, France
| | | |
Collapse
|
10
|
Bertin B, Grenet G, Pizzoglio-Billaudaz V, Lepelley M, Atzenhoffer M, Vial T. Vaccines and Bell's palsy: A narrative review. Therapie 2022; 78:279-292. [PMID: 36038397 PMCID: PMC9341208 DOI: 10.1016/j.therap.2022.07.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2022] [Revised: 07/21/2022] [Accepted: 07/28/2022] [Indexed: 11/16/2022]
Affiliation(s)
- Blandine Bertin
- Pharmacovigilance Center, Hospital University Pharmacotoxicology Department, Hospices civils de Lyon, 69003 Lyon, France
| | - Guillaume Grenet
- Poison control and toxicovigilance center, Hospital University Pharmacotoxicology Department, Hospices civils de Lyon, 69003 Lyon, France; Laboratoire de Biométrie et Biologie Evolutive UMR 5558, CNRS, Université Lyon 1, Université de Lyon, 69100 Villeurbanne, France
| | - Véronique Pizzoglio-Billaudaz
- Pharmacovigilance Center, Hospital University Pharmacotoxicology Department, Hospices civils de Lyon, 69003 Lyon, France
| | - Marion Lepelley
- Clinical Pharmacology and Pharmacovigilance Department, Grenoble Alpes University Hospital, 38000 Grenoble, France
| | - Marina Atzenhoffer
- Pharmacovigilance Center, Hospital University Pharmacotoxicology Department, Hospices civils de Lyon, 69003 Lyon, France
| | - Thierry Vial
- Pharmacovigilance Center, Hospital University Pharmacotoxicology Department, Hospices civils de Lyon, 69003 Lyon, France.
| |
Collapse
|
11
|
Chaurasia B, Chavda V, Lu B, Garg K, Montemurro N. Cognitive deficits and memory impairments after COVID-19 (Covishield) vaccination. Brain Behav Immun Health 2022; 22:100463. [PMID: 35496775 PMCID: PMC9034829 DOI: 10.1016/j.bbih.2022.100463] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2022] [Revised: 04/12/2022] [Accepted: 04/20/2022] [Indexed: 12/11/2022] Open
Abstract
Vaccination is an essential public health strategy to control the 2019 Coronavirus (COVID-19) pandemic. While the benefits of the COVID-19 vaccines far outweigh the risks, side effects continue to be reported in the literature. We report a 65-year-old man who developed cognitive deficits and memory impairments following his first dose of Oxford AstraZeneca vaccine (Covishield). The onset of acute cognitive deficits and memory impairments could be another complication to COVID-19 vaccination that physicians and neurologists need to be warned to. Monitoring the safety of COVID-19 vaccines and describing side effects associated with them is essential to improve safety profiles and enhance public trust.
Collapse
Affiliation(s)
- Bipin Chaurasia
- Department of Neurosurgery, Bhawani Hospital and Research Centre, Birgunj, Nepal
| | - Vishal Chavda
- Department of Pathology, Stanford School of Medicine, Stanford University Medical Center, USA
| | - Bingwei Lu
- Department of Pathology, Stanford School of Medicine, Stanford University Medical Center, USA
| | - Kanwaljeet Garg
- Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India
| | - Nicola Montemurro
- Department of Neurosurgery, Azienda Ospedaliera Universitaria Pisana (AOUP), University of Pisa, Pisa, Italy
| |
Collapse
|
12
|
De novo and relapsed immune thrombocytopenia after COVID-19 vaccines: results of French safety monitoring. Blood 2022; 139:2561-2565. [PMID: 35446373 PMCID: PMC8926428 DOI: 10.1182/blood.2022015470] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Accepted: 02/21/2022] [Indexed: 12/20/2022] Open
|
13
|
Ouldali N, Bagheri H, Salvo F, Antona D, Pariente A, Leblanc C, Tebacher M, Micallef J, Levy C, Cohen R, Javouhey E, Bader-Meunier B, Ovaert C, Renolleau S, Hentgen V, Kone-Paut I, Deschamps N, De Pontual L, Iriart X, Guen CGL, Angoulvant F, Belot A. Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children: A national post-authorization pharmacovigilance study. Lancet Reg Health Eur 2022; 17:100393. [PMID: 35505833 PMCID: PMC9051933 DOI: 10.1016/j.lanepe.2022.100393] [Citation(s) in RCA: 24] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Background Multisystem inflammatory syndrome in children (MIS-C) is the most severe clinical entity associated with pediatric SARS-CoV-2 infection with a putative role of the spike protein into the immune system activation. Whether COVID-19 mRNA vaccine can induce this complication in children is unknown. We aimed to assess the risk of hyper-inflammatory syndrome following COVID-19 mRNA vaccine in children. Methods We conducted a post-authorization national population-based surveillance using the French enhanced pharmacovigilance surveillance system for COVID-19 vaccines. All cases of suspected hyper-inflammatory syndrome following COVID-19 mRNA vaccine in 12–17-year-old children between June 15th, 2021 and January 1st, 2022, were reported. Cases were reviewed according to WHO criteria for MIS-C. The reporting rate of this syndrome was compared to the MIS-C rate per 1,000,000 12–17-year-old children infected by SARS-CoV-2. Findings Up to January 2022, 8,113,058 COVID-19 mRNA vaccine doses were administered to 4,079,234 12–17-year-old children. Among them, 12 presented a hyper-inflammatory syndrome with multisystemic involvement. Main clinical features included male predominance (10/12, 83%), cardiac involvement (10/12, 83%), digestive symptoms (10/12, 83%), coagulopathy (7/12, 58%), cytolytic hepatitis (6/12, 50%), and shock (5/12, 42%). 4/12 (33%) required intensive care unit transfer, and 3/12 (25%) hemodynamic support. All cases recovered. In eight cases, no evidence of previous SARS-CoV-2 infection was found. The reporting rate was 1.5 (95%CI [0.8; 2.6]) per 1,000,000 doses injected, i.e. 2.9 (95%CI [1.5; 5.1]) per 1,000,000 12–17-year-old vaccinated children. As a comparison, 113 MIS-C (95%CI [95; 135]) occurred per 1,000,000 12–17-year-old children infected by SARS-CoV-2. Interpretation Very few cases of hyper-inflammatory syndrome with multi-organ involvement occurred following COVID-19 mRNA vaccine in 12–17-year-old children. The low reporting rate of this syndrome, compared to the rate of post-SARS-CoV-2 MIS-C in the same age-group, largely supports the vaccination in a context of an important circulation of SARS-CoV-2. Funding ESPID Fellowship Award; Grandir–Fonds de Solidarité Pour L'enfance.
Collapse
Affiliation(s)
- Naïm Ouldali
- Assistance Publique-Hôpitaux de Paris, Department of general paediatrics, paediatric infectious disease and internal medicine, Robert Debré university hospital, Université de Paris, Paris, France
- Infectious Diseases Division, CHU Sainte Justine - Montreal University, Montreal, Quebec, Canada
- ACTIV, Association Clinique et Thérapeutique Infantile du Val-de-Marne, Créteil, France
- Université de Paris, INSERM UMR 1123, ECEVE, Paris, France
- Corresponding author at: Assistance Publique-Hôpitaux de Paris, Department of general paediatrics, paediatric infectious disease and internal medicine, Robert Debré university hospital, Université de Paris, Paris, France.
| | - Haleh Bagheri
- Department of Medical and Clinical Pharmacology, Regional Pharmacovigilance Center, CIC 1436, Toulouse University Hospital, France
| | - Francesco Salvo
- INSERM, BPH, U1219, Team Pharmacoepidemiology, Université de Bordeaux, 33000 Bordeaux, France
- Pole de Santé Publique, Service de Pharmacologie Médicale, Regional pharmacovigilance center of Bordeaux, CHU de Bordeaux, 33000 Bordeaux, France
| | - Denise Antona
- Santé Publique France, Agence nationale de Santé publique, Saint-Maurice, France
| | - Antoine Pariente
- Team Pharmacoepidemiology, U1219 BPH Research Center, Bordeaux University, INSERM, Bordeaux, France
| | - Claire Leblanc
- Assistance Publique-Hôpitaux de Paris, Department of general paediatrics, paediatric infectious disease and internal medicine, Robert Debré university hospital, Université de Paris, Paris, France
| | - Martine Tebacher
- Regional pharmacovigilance center of Strasbourg, HUS, Strasbourg, France
| | - Joëlle Micallef
- Marseille University hospital, Clinical pharmacology department Regional Pharmacovigilance Center of Marseille, France
- Aix-Marseille University, INSERM UMR 1106, Marseille, France
| | - Corinne Levy
- ACTIV, Association Clinique et Thérapeutique Infantile du Val-de-Marne, Créteil, France
- Centre Hospitalier Intercommunal, Research Center, Université Paris Est, IMRB-GRC GEMINI, Créteil, France
| | - Robert Cohen
- ACTIV, Association Clinique et Thérapeutique Infantile du Val-de-Marne, Créteil, France
- Centre Hospitalier Intercommunal, Research Center, Université Paris Est, IMRB-GRC GEMINI, Créteil, France
| | - Etienne Javouhey
- Hospices Civils de Lyon, Paediatric Intensive Care Unit, Hopital Femme, Mère Enfant, University of Lyon, Bron, France
- EA 7426 "Pathophysiology of Injury-Induced Immunosuppression", University Claude Bernard Lyon 1, Hospices Civils of Lyon, Lyon, France
| | - Brigitte Bader-Meunier
- Department of Paediatric Hematology-Immunology and Rheumatology, Necker-Enfants Malades Hospital, AP-HP, Paris, France, Reference center for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Paris, France
- Laboratory of Immunogenetics of Paediatric Autoimmunity, Imagine Institute, Paris University, Inserm U 1163, Paris, France
| | - Caroline Ovaert
- Department of Pediatric Cardiology, Hôpital Timone Enfant, AP-HM, Marseille, France
- Aix-Marseille University, MMG, INSERM, Marseille, France
| | - Sylvain Renolleau
- Pediatric Intensive Care Unit, Necker Hospital, AP-HP, Paris University, Paris, France
- Paris University, Paris EA7323, France
| | - Veronique Hentgen
- General Pediatrics department, Versailles Hospital, Paris, France
- CEREMAIA (French reference center for auto-inflammatory diseases and inflammatory amyloidosis), Paris, France
| | - Isabelle Kone-Paut
- CEREMAIA (French reference center for auto-inflammatory diseases and inflammatory amyloidosis), Paris, France
- Pediatric Rheumatology Department, Bicêtre Hospital, APHP, University of Paris Saclay, Kremlin Bicêtre, France
| | - Nina Deschamps
- General Pediatrics department, Saint-Malo Hospital, Saint-Malo, France
| | - Loïc De Pontual
- General Pediatrics and Pediatric emergency department, Jean Verdier Hospital, Bondy, France
| | - Xavier Iriart
- Department of Pediatric and Adult Congenital Cardiology, Bordeaux University Hospital, Pessac, France
- Institut Hospitalo-Universitaire Liryc, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Université, Bordeaux, Pessac, France
- INSERM, Centre de recherche Cardio-Thoracique de Bordeaux, Bordeaux, France
| | - Christelle Gras-Le Guen
- Department of Pediatric Emergency Care, Nantes University Hospital, Nantes F-44000, France
- Obstetrical, Perinatal and Pediatric Epidemiology Research team, Center of Research in Epidemiology and Statistics, Université de Paris, INSERM, Paris F-75004, France
- Inserm CIC 1413, Nantes University Hospital, Nantes F-44000, France
| | - François Angoulvant
- Assistance Publique-Hôpitaux de Paris, Department of general paediatrics, paediatric infectious disease and internal medicine, Robert Debré university hospital, Université de Paris, Paris, France
- INSERM, Centre de Recherche des Cordeliers, UMRS 1138, Sorbonne Université, Université de Paris, Paris, France
| | - Alexandre Belot
- Hospices Civils de Lyon, Paediatric Nephrology, Rheumatology, Dermatology, Hopital Femme, Mère Enfant and Centre International de Recherche en Infectiologie / INSERM U1111, Bron, France
- National Reference Center for Rheumatic and AutoImmune and Systemic Diseases in Children (RAISE), Lyon, France
- International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, 69007 Lyon, France
- Corresponding author at: Hospices Civils de Lyon, Paediatric Nephrology, Rheumatology, Dermatology, Hopital Femme, Mère Enfant and Centre International de Recherche en Infectiologie / INSERM U1111, Bron, France.
| | | |
Collapse
|
14
|
Affiliation(s)
- Philippe Lechat
- Professeur émérite, Université de Paris, 75005 Paris, France.
| |
Collapse
|
15
|
Mettler C, Terrier B, Chouchana L. Comment on: Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study: reply. Rheumatology (Oxford) 2021; 61:e103-e104. [PMID: 34875031 PMCID: PMC8690124 DOI: 10.1093/rheumatology/keab854] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2021] [Accepted: 11/03/2021] [Indexed: 11/13/2022] Open
Affiliation(s)
- Camille Mettler
- Département de Médecine Interne, Centre de Référence National pour les maladies auto-immunes systémiques rares, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Benjamin Terrier
- Département de Médecine Interne, Centre de Référence National pour les maladies auto-immunes systémiques rares, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France.,Université Paris Descartes, Paris, France
| | - Laurent Chouchana
- Département de Pharmacologie, Centre Régional de Pharmacovigilance, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France
| |
Collapse
|
16
|
COVID-19 vaccine post-marketing surveillance: Cardiovascular doctors have a role to play! Arch Cardiovasc Dis 2021; 114:521-523. [PMID: 34535416 PMCID: PMC8423988 DOI: 10.1016/j.acvd.2021.09.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/18/2021] [Revised: 08/31/2021] [Accepted: 09/01/2021] [Indexed: 11/29/2022]
|
17
|
Chouchana L, Canouï E, Batista R, Contejean A, Cariou A, Treluyer JM, Charlier C. Balancing the reactogenicity of the ChAdOx1 nCov-19 vaccine against COVID-19 and the urgent need of a large immunization in healthcare workers. Therapie 2021; 77:371-373. [PMID: 34462137 PMCID: PMC8314864 DOI: 10.1016/j.therap.2021.07.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2021] [Revised: 07/08/2021] [Accepted: 07/20/2021] [Indexed: 12/01/2022]
Affiliation(s)
- Laurent Chouchana
- Regional Center of Pharmacovigilance, Cochin Hospital, AP-HP Centre, Université de Paris, 75014 Paris, France.
| | - Etienne Canouï
- Antimicrobial Stewardship Team, Cochin Hospital, AP-HP Centre, Université de Paris, 75014 Paris, France
| | - Rui Batista
- Pharmacy Department, Cochin Hospital, AP-HP Centre, Université de Paris, 75014 Paris, France
| | - Adrien Contejean
- Antimicrobial Stewardship Team, Cochin Hospital, AP-HP Centre, Université de Paris, 75014 Paris, France; Université de Paris, 75006 Paris, France
| | - Alain Cariou
- Université de Paris, 75006 Paris, France; Medical ICU, Cochin Hospital, AP-HP Centre, Université de Paris, 75014 Paris, France
| | - Jean-Marc Treluyer
- Regional Center of Pharmacovigilance, Cochin Hospital, AP-HP Centre, Université de Paris, 75014 Paris, France; Université de Paris, 75006 Paris, France
| | - Caroline Charlier
- Antimicrobial Stewardship Team, Cochin Hospital, AP-HP Centre, Université de Paris, 75014 Paris, France; Université de Paris, 75006 Paris, France; Institut Pasteur, Biology of Infection Unit, French National Reference Center and WHO Collaborating Center Listeria, Inserm U1117, 75014 Paris, France
| |
Collapse
|
18
|
Pariente A, Bezin J. Evaluation of Covid-19 vaccines: Pharmacoepidemiological aspects. Therapie 2021; 76:305-309. [PMID: 34119319 PMCID: PMC8103672 DOI: 10.1016/j.therap.2021.05.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2021] [Accepted: 05/03/2021] [Indexed: 01/18/2023]
Abstract
The marketing authorization granted to SARS-Cov-2 vaccines was accompanied by reinforced safety monitoring plans. These plans' implementation was part of the usual logic of post-marketing surveillance of new and innovative health products. It was especially adapted to the context of post-marketing monitoring of drugs developed according to the usual scientific quality standards but in an accelerated schedule. In Europe, the reinforced surveillance system relies on the complementary strengths of pharmacovigilance and pharmacoepidemiology. If the performances of pharmacovigilance monitoring are incomparable for the detection of safety signals relating to rare events of atypical presentation, it needs to be completed with pharmacoepidemiology activities for more common events, either multifactorial or frequently classified as idiopathic. The pharmacoepidemiological monitoring developed in Europe was elaborated before the first SARS-Cov-2 vaccines where marketed, taking into account the lessons learned from the vaccination campaign against 2009 A (H1N1) influenza. It includes numerous academic studies as well as studies performed within vaccines risk management plans. In terms of safety, those defined a priori mostly concerns a list of pre-established health events of specific interest. Aside of these planned activities, ad-hoc studies will be latter developed on purpose to investigate safety signals or potential signals that could be identified as the result of pharmacovigilance activities. Aside of these regulated activities, as for today, very few studies have been published regarding SARS-Cov-2 vaccines; most of the existing consist in preprints that should be considered with caution. Pharmacoepidemiology of vaccines is thought to allow near-real time monitoring that needs sufficient time to provide with valid results. In the constant urge for information that accompanies COVID-related science, it is important not to make haste the enemy of speed and to let pharmacoepidemiology provides with what it is expected to do: rock-solid scientific information contributing to evidence-based decision-making.
Collapse
Affiliation(s)
- Antoine Pariente
- University Bordeaux, Inserm, BPH, U1219, Team Pharmacoepidemiology, 33000 Bordeaux, France; CHU de Bordeaux, pôle de santé publique, service de pharmacologie médicale, unité de pharmaco-épidémiologie et bon usage du médicament, 33000 Bordeaux, France.
| | - Julien Bezin
- University Bordeaux, Inserm, BPH, U1219, Team Pharmacoepidemiology, 33000 Bordeaux, France; CHU de Bordeaux, pôle de santé publique, service de pharmacologie médicale, unité de pharmaco-épidémiologie et bon usage du médicament, 33000 Bordeaux, France
| |
Collapse
|
19
|
Montastruc JL, Lafaurie M, de Canecaude C, Montastruc F, Bagheri H, Durrieu G, Sommet A. COVID-19 vaccines: A perspective from social pharmacology. Therapie 2021; 76:311-315. [PMID: 34119317 PMCID: PMC8161798 DOI: 10.1016/j.therap.2021.05.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2021] [Accepted: 05/04/2021] [Indexed: 12/03/2022]
Abstract
Social pharmacology is a branch of clinical pharmacology, which depicts relationships between society and drugs and in particular factors, reasons, social consequences of drug use as well as representations of drugs in the society. Recent development and marketing of coronavirus disease 2019 (COVID-19) vaccines raises a number of questions of social pharmacology: are vaccines drugs like any other? What is their perception at the individual, population and societal levels? How do individuals perceive the risks and benefits of these vaccines? What is the perception at the societal level? What is the individual and societal acceptability of these vaccines during a pandemic? All these questions are discussed in the light of recent data. A number of proposals, both at the individual and at the collective or population level, are formulated to help solve these problems of social pharmacology.
Collapse
Affiliation(s)
- Jean-Louis Montastruc
- Service de pharmacologie médicale et clinique, centre de pharmacovigilance, de pharmacoépidémiologie et d'informations sur le médicament, CIC INSERM 1436, centre hospitalier universitaire, faculté de médecine, 31000 Toulouse, France.
| | - Margaux Lafaurie
- Service de pharmacologie médicale et clinique, centre de pharmacovigilance, de pharmacoépidémiologie et d'informations sur le médicament, CIC INSERM 1436, centre hospitalier universitaire, faculté de médecine, 31000 Toulouse, France
| | - Claire de Canecaude
- Service de pharmacologie médicale et clinique, centre de pharmacovigilance, de pharmacoépidémiologie et d'informations sur le médicament, CIC INSERM 1436, centre hospitalier universitaire, faculté de médecine, 31000 Toulouse, France
| | - François Montastruc
- Service de pharmacologie médicale et clinique, centre de pharmacovigilance, de pharmacoépidémiologie et d'informations sur le médicament, CIC INSERM 1436, centre hospitalier universitaire, faculté de médecine, 31000 Toulouse, France
| | - Haleh Bagheri
- Service de pharmacologie médicale et clinique, centre de pharmacovigilance, de pharmacoépidémiologie et d'informations sur le médicament, CIC INSERM 1436, centre hospitalier universitaire, faculté de médecine, 31000 Toulouse, France
| | - Geneviève Durrieu
- Service de pharmacologie médicale et clinique, centre de pharmacovigilance, de pharmacoépidémiologie et d'informations sur le médicament, CIC INSERM 1436, centre hospitalier universitaire, faculté de médecine, 31000 Toulouse, France
| | - Agnès Sommet
- Service de pharmacologie médicale et clinique, centre de pharmacovigilance, de pharmacoépidémiologie et d'informations sur le médicament, CIC INSERM 1436, centre hospitalier universitaire, faculté de médecine, 31000 Toulouse, France
| |
Collapse
|
20
|
Molimard M, Richard V, Cracowski JL. COVID-19: Pharmacology has kept the science ship running during the storm. Therapie 2021; 76:275-276. [PMID: 34119318 PMCID: PMC8161723 DOI: 10.1016/j.therap.2021.05.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Accepted: 05/20/2021] [Indexed: 11/02/2022]
Affiliation(s)
- Mathieu Molimard
- University Bordeaux, INSERM, BPH, U1219, Team Pharmacoepidemiology, 146, rue Leo Saignat, 33000 Bordeaux, France.
| | - Vincent Richard
- Normandy University, UniRouen, Inserm U1096 EnVI & Department of Pharmacology, 76000 Rouen, France
| | | |
Collapse
|